FindTrial
Sign In

JK07

DRUG4 trials

Sponsors

Salubris Biotherapeutics Inc

Conditions

Group 2 Pulmonary HypertensionHFpEF - Heart Failure With Preserved Ejection FractionHFrEF - Heart Failure With Reduced Ejection FractionHeart Failure With Preserved Ejection FractionHeart Failure With Reduced Ejection Fraction

Phase 1

Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
CompletedNCT04210375
Salubris Biotherapeutics IncHeart Failure With Reduced Ejection Fraction
Start: 2020-09-21End: 2023-07-07Updated: 2025-07-09
Single-Ascending Dose Study of JK07 in Subjects With HFpEF
WithdrawnNCT05322616
Salubris Biotherapeutics IncHeart Failure With Preserved Ejection Fraction
Start: 2022-10-21End: 2023-05-26Updated: 2023-05-31

Phase 2

Study of JK07 in Patients With Chronic Heart Failure
Active, not recruitingNCT06369298
Salubris Biotherapeutics IncHeart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Start: 2024-03-28End: 2026-10-31Target: 282Updated: 2026-05-22
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
WithdrawnNCT07221513
Salubris Biotherapeutics IncGroup 2 Pulmonary Hypertension, HFpEF - Heart Failure With Preserved Ejection Fraction, HFrEF - Heart Failure With Reduced Ejection Fraction
Start: 2025-12-15End: 2026-04-16Updated: 2026-05-15

Related Papers

Single Ascending-Dose Study of Selective ErbB4 Agonist JK07 in Heart Failure With Reduced Ejection Fraction
JACC Basic to Translational Science2025-07-291 citations